Biogen (BIIB) Tops Q1 EPS by 13c, Miss on Revenues

Biogen (BIIB) PT Lowered to $311 at RBC Capital

RBC Capital lowered its price target on Biogen (NASDAQ: BIIB) to $311.00 (from $316.00) while maintaining a Sector Perform rating.

Analyst Brian Abrahams said Q1 softness stems from Spinraza and seasonality.

Biogen (BIIB) PT Lowered to $375 at Oppenheimer

Oppenheimer lowered its price target on Biogen (NASDAQ: BIIB) to $375.00 (from $400.00) while maintaining a Outperform rating.

Analyst Jay Olson commented, "A solid 1Q update addressed investor concerns on multiple fronts with decent financial results featuring an EPS beat of $6.05 vs $5.93E consensus and... More

Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q

Piper Jaffray reiterated an Overweight rating and $407.00 price target on Biogen (NASDAQ: BIIB) following the company's 1Q earnings report. BIIB posted total revenue of $3,131M, missing consensus $3,152M but beating Piper Jaffray's $3,080M estimate. Non-GAAP EPS of $6.05 easily beat consensus $5.93.

BIIB's anti-CD20... More

Amid drug price worries, earnings to test U.S. pharma, biotech shares

By Lewis Krauskopf

NEW YORK (Reuters) - Major U.S. pharmaceutical and biotechnology companies, whose shares have been laggards even in a sluggish market, face a litmus test in the corporate earnings season as investors already gun-shy over concerns about pressures on drug prices prepare to give a sharp eye for both hits and misses.

As a group, pharmaceutical stocks in the S&P 500 are down about 4 percent so far this year, while S&P biotech stocks are off about 6 percent. Even in a choppy overall market, biotech and pharma have underperformed the... More

Biogen (BIIB) weekly option implied volatility elevated into Q1

Biogen (NASDAQ: BIIB) April weekly call option implied volatility is at 58, May is at 35; compared to its 52-week range of 21 to 38 into the expected release of Q1 results before the market open on April 24.

Nomura/Instinet Reiterates Buy on Biogen (BIIB) Following Announced IONS Collaboration

Nomura/Instinet reiterated a Buy rating and $420.00 price target on Biogen (NASDAQ: BIIB) following the company's announced details of an expanded collaboration with IONS to develop CNS-delivered antisense oligonucleotides. The deal was not considered in BIIBs prior financial guidance.

The IONS... More

Biogen (BIIB) Reports New SPINRAZA (nusinersen) Data at AAN Meetings

Biogen (NASDAQ: BIIB) today announced new findings detailing the benefits that SPINRAZA® (nusinersen) demonstrates for both infantile- and later-onset spinal muscular atrophy (SMA) populations, including improvement in motor function as well as increased survival for the most severely affected. These findings are based on interim results from the SHINE open-label extension study and an analysis of SPINRAZAs... More

SAGE Therapeutics (SAGE) Defended at Raymond James, Says Selloff is Overreaction

Raymond James maintains Strong Buy on Sage Therapeutics (NASDAQ: SAGE) price target of $206.00.

Analyst Laura Chico believes the 10%+ selloff is an overreaction to a post-close Thursday Form 4 filing highlighting a insider sale by a director... More

Biogen (BIIB) Reports $1B Payment to Ionis Pharma (IONS) for Expanded Collaboration on Neurological Diseases Drug Development

(Updated - April 20, 2018 6:54 AM EDT)

Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases. This collaboration capitalizes on Biogens expertise in neuroscience research and... More